Endonovo Therapeutics Inc. (ENDV) to Distribute No
Post# of 416
(Total Views: 574)
Posted On: 05/31/2019 4:12:33 PM
Endonovo Therapeutics Inc. (ENDV) to Distribute Non-Invasive, Wearable Therapeutic Devices to Nation’s Veteran Health Care Facilities
- Endonovo’s flagship product, SofPulse, is an easy-to-place, non-invasive device delivering pulsed electromagnetic frequencies to enhance post-surgical recovery
- The company’s agreement with Veterans Healthcare Supply Solutions Inc. includes distribution of SofPulse to Veterans Administration facilities and Department of Defense health care facilities
- Treatment with SofPulse allows patients to better manage post-operative pain without the adverse side effects of narcotics and anti-inflammatory medications
- Endonovo holds patents and trademarks for several proprietary technologies and devices
Endonovo Therapeutics Inc. (OTCQB: ENDV) is a commercial stage developer of non-invasive medical devices designed to deliver proprietary, patent protected Electroceutical Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders. As an innovative biotechnology company, Endonovo is harnessing bioelectricity to restore key electrochemical processes that initiate the anti-inflammatory and growth factor cascades necessary for healing to occur.
The long-term agreement recently signed with Veterans Healthcare Supply Solutions Inc. (“VHSS”) to directly distribute SofPulse devices to Veterans Administration facilities and Department of Defense health care facilities extends beyond traditional distribution methods, Endonovo CEO Alan Collier said in a news release (http://nnw.fm/0nEHv).
“The team at VHSS have streamlined and improved the sales, marketing and distribution of medical devices to VA and DoD facilities. VHSS is a true leader in the space and we are thrilled to have the capacity to support their mission,” Collier stated in a news release. “This agreement, which includes direct delivery to all medical facilities, extends beyond traditional distribution and includes access to their 900 Federal Contract Officers as well as their distribution center with a state-of-the-art ERP and WMS Systems.”
Endonovo’s flagship product, SofPulse, is an easy-to-place, non-invasive device delivering pulsed electromagnetic frequencies to enhance post-surgical recovery, and it can be used as a standalone therapy or integrated into any treatment protocol. SofPulse uses targeted microcurrents to transmit gentle pulses to the tissue to help reduce swelling and speed up the natural recovery process.
“VHSS is excited to partner with Endonovo, as our primary goal is providing leading edge products and services to eligible federal government health care constituents,” added Gary Skura, VHSS president and retired Navy pilot with over 30 years of health care distribution experience. “Our new partnership with Endonovo will certainly allow us to further continue our core objectives.”
Endonovo’s Electroceutical Therapy is cleared by the U.S. Federal Drug Administration (FDA) for the palliative treatment of post-surgical pain and edema (swelling) and is CE-marked in the European Economic Area (EEA) for the promotion of wound healing and the palliative treatment of post-surgical pain and edema. The Centers for Medicare and Medicaid Services (CMS) also has national coverage determination for the reimbursement of Electroceutical Therapy for the treatment of chronic wounds.
For more information, visit the company’s website at www.Endonovo.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Endonovo’s flagship product, SofPulse, is an easy-to-place, non-invasive device delivering pulsed electromagnetic frequencies to enhance post-surgical recovery
- The company’s agreement with Veterans Healthcare Supply Solutions Inc. includes distribution of SofPulse to Veterans Administration facilities and Department of Defense health care facilities
- Treatment with SofPulse allows patients to better manage post-operative pain without the adverse side effects of narcotics and anti-inflammatory medications
- Endonovo holds patents and trademarks for several proprietary technologies and devices
Endonovo Therapeutics Inc. (OTCQB: ENDV) is a commercial stage developer of non-invasive medical devices designed to deliver proprietary, patent protected Electroceutical Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders. As an innovative biotechnology company, Endonovo is harnessing bioelectricity to restore key electrochemical processes that initiate the anti-inflammatory and growth factor cascades necessary for healing to occur.
The long-term agreement recently signed with Veterans Healthcare Supply Solutions Inc. (“VHSS”) to directly distribute SofPulse devices to Veterans Administration facilities and Department of Defense health care facilities extends beyond traditional distribution methods, Endonovo CEO Alan Collier said in a news release (http://nnw.fm/0nEHv).
“The team at VHSS have streamlined and improved the sales, marketing and distribution of medical devices to VA and DoD facilities. VHSS is a true leader in the space and we are thrilled to have the capacity to support their mission,” Collier stated in a news release. “This agreement, which includes direct delivery to all medical facilities, extends beyond traditional distribution and includes access to their 900 Federal Contract Officers as well as their distribution center with a state-of-the-art ERP and WMS Systems.”
Endonovo’s flagship product, SofPulse, is an easy-to-place, non-invasive device delivering pulsed electromagnetic frequencies to enhance post-surgical recovery, and it can be used as a standalone therapy or integrated into any treatment protocol. SofPulse uses targeted microcurrents to transmit gentle pulses to the tissue to help reduce swelling and speed up the natural recovery process.
“VHSS is excited to partner with Endonovo, as our primary goal is providing leading edge products and services to eligible federal government health care constituents,” added Gary Skura, VHSS president and retired Navy pilot with over 30 years of health care distribution experience. “Our new partnership with Endonovo will certainly allow us to further continue our core objectives.”
Endonovo’s Electroceutical Therapy is cleared by the U.S. Federal Drug Administration (FDA) for the palliative treatment of post-surgical pain and edema (swelling) and is CE-marked in the European Economic Area (EEA) for the promotion of wound healing and the palliative treatment of post-surgical pain and edema. The Centers for Medicare and Medicaid Services (CMS) also has national coverage determination for the reimbursement of Electroceutical Therapy for the treatment of chronic wounds.
For more information, visit the company’s website at www.Endonovo.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Endonovo Therapeutics, Inc. (ENDV) Stock Research Links
Scroll down for more posts ▼